FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2060672207> ?p ?o ?g. }

• W2060672207 endingPage "885" @default.
• W2060672207 startingPage "877" @default.
• W2060672207 abstract "Purpose To review clinical outcomes of moderate dose escalation using high-dose radiation therapy (HDRT) in the setting of concurrent temozolomide (TMZ) in patients with newly diagnosed glioblastoma multiforme (GBM), compared with standard-dose radiation therapy (SDRT). Methods and Materials Adult patients aged <70 years with biopsy-proven GBM were treated with SDRT (60 Gy at 2 Gy per fraction) or with HDRT (>60 Gy) and TMZ from 2000 to 2012. Biological equivalent dose at 2-Gy fractions was calculated for the HDRT assuming an α/β ratio of 5.6 for GBM. Results Eighty-one patients received SDRT, and 128 patients received HDRT with a median (range) biological equivalent dose at 2-Gy fractions of 64 Gy (61-76 Gy). Overall median follow-up time was 1.10 years, and for living patients it was 2.97 years. Actuarial 5-year overall survival (OS) and progression-free survival (PFS) rates for patients that received HDRT versus SDRT were 12.4% versus 13.2% (P=.71), and 5.6% versus 4.1% (P=.54), respectively. Age (P=.001) and gross total/near-total resection (GTR/NTR) (P=.001) were significantly associated with PFS on multivariate analysis. Younger age (P<.0001), GTR/NTR (P<.0001), and Karnofsky performance status ≥80 (P=.001) were associated with improved OS. On subset analyses, HDRT failed to improve PFS or OS for those aged <50 years or those who had GTR/NTR. Conclusion Moderate radiation therapy dose escalation above 60 Gy with concurrent TMZ does not seem to improve clinical outcomes for patients with GBM. To review clinical outcomes of moderate dose escalation using high-dose radiation therapy (HDRT) in the setting of concurrent temozolomide (TMZ) in patients with newly diagnosed glioblastoma multiforme (GBM), compared with standard-dose radiation therapy (SDRT). Adult patients aged <70 years with biopsy-proven GBM were treated with SDRT (60 Gy at 2 Gy per fraction) or with HDRT (>60 Gy) and TMZ from 2000 to 2012. Biological equivalent dose at 2-Gy fractions was calculated for the HDRT assuming an α/β ratio of 5.6 for GBM. Eighty-one patients received SDRT, and 128 patients received HDRT with a median (range) biological equivalent dose at 2-Gy fractions of 64 Gy (61-76 Gy). Overall median follow-up time was 1.10 years, and for living patients it was 2.97 years. Actuarial 5-year overall survival (OS) and progression-free survival (PFS) rates for patients that received HDRT versus SDRT were 12.4% versus 13.2% (P=.71), and 5.6% versus 4.1% (P=.54), respectively. Age (P=.001) and gross total/near-total resection (GTR/NTR) (P=.001) were significantly associated with PFS on multivariate analysis. Younger age (P<.0001), GTR/NTR (P<.0001), and Karnofsky performance status ≥80 (P=.001) were associated with improved OS. On subset analyses, HDRT failed to improve PFS or OS for those aged <50 years or those who had GTR/NTR. Moderate radiation therapy dose escalation above 60 Gy with concurrent TMZ does not seem to improve clinical outcomes for patients with GBM." @default.
• W2060672207 created "2016-06-24" @default.
• W2060672207 creator A5001298239 @default.
• W2060672207 creator A5008096514 @default.
• W2060672207 creator A5012482548 @default.
• W2060672207 creator A5020604679 @default.
• W2060672207 creator A5022047595 @default.
• W2060672207 creator A5028100054 @default.
• W2060672207 creator A5034637646 @default.
• W2060672207 creator A5038749547 @default.
• W2060672207 creator A5039358235 @default.
• W2060672207 creator A5044289612 @default.
• W2060672207 creator A5054310342 @default.
• W2060672207 creator A5065920190 @default.
• W2060672207 creator A5068905445 @default.
• W2060672207 creator A5075996643 @default.
• W2060672207 creator A5077868821 @default.
• W2060672207 creator A5083473334 @default.
• W2060672207 date "2014-11-01" @default.
• W2060672207 modified "2023-10-17" @default.
• W2060672207 title "Radiation Therapy Dose Escalation for Glioblastoma Multiforme in the Era of Temozolomide" @default.
• W2060672207 cites W1975907146 @default.
• W2060672207 cites W1978202663 @default.
• W2060672207 cites W1986718289 @default.
• W2060672207 cites W2002125856 @default.
• W2060672207 cites W2009303494 @default.
• W2060672207 cites W2020784028 @default.
• W2060672207 cites W2027575682 @default.
• W2060672207 cites W2029445057 @default.
• W2060672207 cites W2032944619 @default.
• W2060672207 cites W2033128037 @default.
• W2060672207 cites W2034931822 @default.
• W2060672207 cites W2036560693 @default.
• W2060672207 cites W2052980985 @default.
• W2060672207 cites W2056897366 @default.
• W2060672207 cites W2060551076 @default.
• W2060672207 cites W2082463337 @default.
• W2060672207 cites W2084859122 @default.
• W2060672207 cites W2087523848 @default.
• W2060672207 cites W2096287682 @default.
• W2060672207 cites W2103634316 @default.
• W2060672207 cites W2105100844 @default.
• W2060672207 cites W2113012900 @default.
• W2060672207 cites W2154853471 @default.
• W2060672207 cites W2158681922 @default.
• W2060672207 cites W2161289668 @default.
• W2060672207 cites W2162496354 @default.
• W2060672207 cites W2164475669 @default.
• W2060672207 cites W2170775247 @default.
• W2060672207 cites W4240369366 @default.
• W2060672207 cites W80380620 @default.
• W2060672207 doi "https://doi.org/10.1016/j.ijrobp.2014.07.014" @default.
• W2060672207 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25257812" @default.
• W2060672207 hasPublicationYear "2014" @default.
• W2060672207 type Work @default.
• W2060672207 sameAs 2060672207 @default.
• W2060672207 citedByCount "49" @default.
• W2060672207 countsByYear W20606722072014 @default.
• W2060672207 countsByYear W20606722072015 @default.
• W2060672207 countsByYear W20606722072016 @default.
• W2060672207 countsByYear W20606722072017 @default.
• W2060672207 countsByYear W20606722072018 @default.
• W2060672207 countsByYear W20606722072019 @default.
• W2060672207 countsByYear W20606722072020 @default.
• W2060672207 countsByYear W20606722072021 @default.
• W2060672207 countsByYear W20606722072022 @default.
• W2060672207 countsByYear W20606722072023 @default.
• W2060672207 crossrefType "journal-article" @default.
• W2060672207 hasAuthorship W2060672207A5001298239 @default.
• W2060672207 hasAuthorship W2060672207A5008096514 @default.
• W2060672207 hasAuthorship W2060672207A5012482548 @default.
• W2060672207 hasAuthorship W2060672207A5020604679 @default.
• W2060672207 hasAuthorship W2060672207A5022047595 @default.
• W2060672207 hasAuthorship W2060672207A5028100054 @default.
• W2060672207 hasAuthorship W2060672207A5034637646 @default.
• W2060672207 hasAuthorship W2060672207A5038749547 @default.
• W2060672207 hasAuthorship W2060672207A5039358235 @default.
• W2060672207 hasAuthorship W2060672207A5044289612 @default.
• W2060672207 hasAuthorship W2060672207A5054310342 @default.
• W2060672207 hasAuthorship W2060672207A5065920190 @default.
• W2060672207 hasAuthorship W2060672207A5068905445 @default.
• W2060672207 hasAuthorship W2060672207A5075996643 @default.
• W2060672207 hasAuthorship W2060672207A5077868821 @default.
• W2060672207 hasAuthorship W2060672207A5083473334 @default.
• W2060672207 hasConcept C126322002 @default.
• W2060672207 hasConcept C143998085 @default.
• W2060672207 hasConcept C2776194525 @default.
• W2060672207 hasConcept C2777389519 @default.
• W2060672207 hasConcept C2989005 @default.
• W2060672207 hasConcept C502942594 @default.
• W2060672207 hasConcept C509974204 @default.
• W2060672207 hasConcept C71924100 @default.
• W2060672207 hasConceptScore W2060672207C126322002 @default.
• W2060672207 hasConceptScore W2060672207C143998085 @default.
• W2060672207 hasConceptScore W2060672207C2776194525 @default.
• W2060672207 hasConceptScore W2060672207C2777389519 @default.
• W2060672207 hasConceptScore W2060672207C2989005 @default.
• W2060672207 hasConceptScore W2060672207C502942594 @default.

• next